The Potential for Improved Processes, Outcomes, and Economics of Health Care
DOGE hopes to solve rampant inefficiencies in US healthcare that contribute to unsustainable costs and a broken system by cutting spending and administrative waste.
3 Things You Should Know About Adverse Events With Targeted Therapies for DLBCL
Tips from experts on how to think about and manage adverse events in patients with diffuse large B-cell lymphoma.
3 Things You Should Know About Identifying and Treating Epithelioid Sarcoma
Experts discuss epithelioid sarcoma diagnosis, management, and targeted therapies, and highlight 3 things everyone should know about treatment.
Advancing the MZL Landscape Through the MZL Workshop
Davide Rossi, MD, spoke about the impact of the MZL workshop and his hopes for the future of treatment and medicine in MZL.
Pinpointing Ways to Overcome Challenges in MZL
As MZL is such a rare subtype of lymphoma, it can be hard to find or begin trials geared specifically toward this population.
Outlining Incidence Trends and Disparities of MZL
Potential contributing factors of marginal zone lymphoma (MZL) were highlighted in a recent discussion with James R. Cerhan, MD, PhD.
Highlighting Quality of Life Considerations for MZL Treatment
Juan Alderuccio, MD, discussed treatment strategies for MZL, particularly as they relate to quality of life, and the role of prognosis models on treatment.
Creating a Collaborative Edge Through the MZL Workshop
Julie M. Vose, MD, MBA, answered questions about the significance and potential impact of MZL Workshop.
Nodal Marginal Zone Lymphoma and Its Diagnostic Challenges
A pathologist discusses the challenges of diagnosing nodal MZL, including its lack of specific defining characteristics.
Insights, Knowledge Gaps, and Priorities in Marginal Zone Lymphoma Research
Marginal Zone Lymphoma experts discussed recent advancements in all areas of MZL, while calling attention to gaps in knowledge in the 2024 MZL Scientific Workshop.
MZL Workshop Paves the Way for Better Treatment Options
Thomas Habermann, MD, discusses the significance of the MZL Workshop and its contributions to advancing research and improving outcomes.
MZL Expert Insights Summit Sponsored by the Lymphoma Research Foundation
Julie M. Vose, MD, MBA, discussed MZL research and future directions in the February Letter to Readers.
